A seasoned physician-scientist who has led multiple antiviral and vaccine programs from early-stage research through late-stage clinical trials and NDA/BLA. He has held executive positions at Merck, and CEO positions at Red Queen, Diosynvax, and Ansun Biopharma. His background includes BARDA and NIH-funding, and capital raises in both public and private Biotech Companies.

Seasoned biopharma executive with over 30 years of commercialization and business development experience. Led the team that took Enbrel over the billion-dollar revenue threshold. Has negotiated licensing agreements with major biopharma companies while at Vical and Oncolytics.

Internationally recognized immunologist and virologist. Professor at Oregon Health and Science University where he has conducted leading research in infectious disease and cancer immunotherapy.

Co-founder of Vir Biotechnology.